Was leistet die pneumologische Rehabilitation?

Was ist neu?

Lungenfibrose Es zeigt sich eine zunehmende Evidenz bezüglich der Wirksamkeit eines pneumologischen Rehabilitationsprogramms (PR) bei anderen pneumologischen Erkrankungen als der COPD (chronic obstructive pulmonary disease). Aktuelle Studien berichten über positive Effekte von strukturierten PR-Programmen bei Lungenfibrose- und Asthmapatienten.

Asthma bronchiale Es konnte gezeigt werden, dass auch Patienten mit moderatem bis schwerem Asthma signifikant im Hinblick auf die Asthmakontrolle von einem PR-Programm profitieren.

Telemedizin meets pneumologische Rehabilitation Bei COPD-Patienten kann ein ergänzendes „digitales Übungsprogramm“ im Vergleich zu einer alleinigen PR-Maßnahme zu größeren Benefits beitragen.

COVID-19 Es gibt erste Hinweise darauf, dass an COVID-19 Erkrankte von einer PR profitieren können. Das aktuelle Positionspapier der deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zum Thema Empfehlungen zur PR bei COVID-19 beschreibt, dass rehabilitative Therapien bereits auf der Normalstation bzw. Intensivstation indiziert sind und sich als pneumologische Frührehabilitation im Akutkrankenhaus und als Anschlussheilbehandlung oder Reha-Heilverfahren in PR-Kliniken fortsetzen sollten.

Abstract

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has stated that pulmonary rehabilitation (PR) is the most effective therapeutic intervention to reduce dyspnoea and to improve physical performance and quality of life for patients with obstructive lung disease.

New innovative studies raised in the area of PR:

1) Pulmonary fibrosis & asthma bronchiale – While PR is recommended for chronic respiratory diseases other than COPD (chronic obstructive pulmonary disease) in the respective disease-specific treatment guidelines, PR in some pathologies is underrated. For example, there is a growing body of evidence showing the effectiveness of structured and multidisciplinary PR programs in pulmonary fibrosis and asthma bronchial patients;

2) Coronavirus SARS-CoV-2 – There is preliminary evidence that COVID-19 patients can benefit from a PR program. The current COVID-19 position paper of the German Respiratory Society e. V. (DGP) regarding PR recommendations suggests that early rehabilitative therapies are already indicated during hospitalisation on the normal or intensive care unit and that rehabilitative interventions should be continued after discharge as a follow-up treatment in PR centres in order to reduce long-term consequences of COVID-19 disease;

3) Telehealth meets PR – To further improve the effectiveness of PR in COPD patients using recent technologies, a supplementary “digital exercise program” can contribute to greater benefits compared to PR alone.

Schlüsselwörter

pneumologische Rehabilitation - pulmonale Fibrose - Asthma bronchiale - COVID-19 - Telemedizin

Key words

pulmonary rehabilitation - pulmonary fibrosis - asthma bronchiale - COVID-19, telehealth

Publication History

Article published online:
30 November 2020

• Literatur

• 1 Spruit MA, Singh SJ, Garvey C. et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-e64
• 2 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease – 2020 Report. 2020 https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf ; Stand: 12.09.2020
• 3 Raghu G, Collard HR, Egan JJ. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824
• 4 Global Initiative for Asthma. Global strategy for asthma management and prevention – Report 2020. 2020 https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf ; Stand: 12.09.2020
• 5 Jarosch I, Schneeberger T, Gloeckl R. et al. Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. J Clin Med 2020; 9: 1567
• 6 Perez-Bogerd S, Wuyts W, Barbier V. et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 2018; 19: 182
• 7 Lingner H, Ernst S, Groβhennig A. et al. Asthma control and health-related quality of life one year after inpatient pulmonary rehabilitation: the ProKAR Study. J Asthma 2015; 52: 614-621
• 8 Schneeberger T, Jarosch I, Moll J. et al. Increased asthma control after a 3-week inpatient pulmonary rehabilitation program. Respir Med 2020; 165: 105930
• 9 Rutkowski S, Rutkowska A, Kiper P. et al. Virtual Reality Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis 2020; 15: 117-124
• 10 Sutanto YS, Makhabah DN, Aphridasari J. et al. Videogame assisted exercise training in patients with chronic obstructive pulmonary disease: A preliminary study. Pulmonology 2019; 25: 275-282
• 11 Carda S, Invernizzi M, Bavikatte G. et al. The role of physical and rehabilitation medicine in the COVID-19 pandemic: the clinician’s view. Ann Phys Rehabil Med 2020; DOI: S1877-0657(20)30076-2.
• 12 Kenn K, Gloeckl R, Behr J. Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis – a review. Respiration 2013; 86: 89-99
• 13 Liu K, Zhang W, Yang Y. et al. Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study. Complement Ther Clin Pract 2020; 39: 101166
• 14 Glöckl R, Buhr-Schinner H, Koczulla AR. et al DGP Empfehlungen zur pneumologischen Rehabilitation bei COVID-19. 2020 https://pneumologie.de/fileadmin/user_upload/COVID-19/20200604_DGP_Reha_bei_COVID-19.pdf ; Stand: 12.09.2020
• 15 Celli B, Fabbri LM. Urgent need of a management plan for survivors of COVID-19. Eur Respir J 2020; 55: 2000764
• 16 Klok FA, Boon GJAM, Barco S. et al. The Post-COVID-19 Functional Status (PCFS) Scale: a tool to measure functional status over time after COVID-19. Eur Respir J 2020; 56: 2001494